Observational Study
Copyright ©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 612-622
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.612
Table 1 Demographic, lifestyle and general health comorbidities of participants according to the presence of nonalcoholic fatty liver disease

All (n = 589)
Non-NAFLD (n = 354)
NAFLD (n = 235)
P value
Age, mean ± SD59.97 ± 6.9759.99 ± 7.4059.94 ± 6.290.3959
Male, %254 (43.12%)131 (37.01%)123 (52.34%)0.0002
White, %564 (95.76%)340 (96.05%)224 (95.32%)0.6686
Smoking status, %
Current70 (11.90%)47 (13.31%)23 (9.79%)0.1958
Former239 (40.65%)141 (39.94%)98 (41.70%)0.6706
Non-smoker279 (47.45%)165 (46.74%)114 (48.51%)0.674
Regular exercise, %
Physically Inactive171 (29.03%)85 (24.01%)86 (36.60%)0.001
Moderate physical activity230 (39.05%)139 (39.27%)91 (38.72%)0.8949
Ideal physical activity188 (31.92%)130 (36.72%)58 (24.68%)0.0021
Obesity, % BMI
Lean270 (45.84%)255 (72.03%)15 (6.38%)< 0.0001
Overweight234 (39.73%)99 (27.97%)135 (57.45%)< 0.0001
Obese85 (14.43%)0 (0.00%)85 (36.17%)< 0.0001
History of CVD, %40 (6.79%)23 (6.50%)17 (7.23%)0.7278
History of arthritis, %68 (11.54%)39 (11.02%)29 (12.34%)0.6226
History of cancer (any), %97 (16.47%)48 (13.56%)49 (20.85%)0.0195
Insulin resistance, %157 (26.66%)48 (13.56%)109 (46.38%)< 0.0001
Hypertension, %117 (19.86%)66 (18.64%)51 (21.70%)0.3623
Hyperlipidemia, %446 (75.72%)245 (69.21%)201 (85.53%)< 0.0001
Diabetes, %74 (12.56%)19 (5.37%)55 (23.40%)< 0.0001
Metabolic syndrome1, %125 (21.26%)23 (6.52%)102 (43.40%)< 0.0001
BDI, mean ± SD4.00 ± 3.713.67 ± 3.624.49 ± 3.800.0041